All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Linda Martin, MD, MPH
Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ethicon: Speaker (Ongoing); Genentech: Advisory Board (Ongoing), Speaker (Ongoing); ontarget laboratories: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Michael Archer, DO

Presentations

1. Standards and Compliance -- What and Why?
   Timothy W. Mullett, MD, MBA, FACS
    
2. Does Occult Nodal Disease Following Sublobar Resection for Clinical T1a-b Non-Small Cell Lung Cancer Necessitate Conversion to Lobectomy?
   Michael Eisenberg, MD
    
3. Invited Discussant
   Patricia A. Thistlethwaite, MD-PhD
    
4. The Association of Participation in a Quality Collaborative and Value in Surgery for Lung Cancer
   Sidra Bonner, MD, MPH, MS
    
5. Association Between the New Commission on Cancer Lymph Node Sampling Standards and Survival for Lung Cancer Resections at a Dedicated Cancer Center
   Benjamin J. Resio, MD
    
6. DEBATE: Is 3N2 + 1N1 the "Right" Standard for Quality Lung Cancer Surgery? YES
   Frank C. Detterbeck, MD
    
7. DEBATE: Is 3N2 + 1N1 the "Right" Standard for Quality Lung Cancer Surgery? NO
   Raja Flores, MD